



# Change in number of shares and votes in Episurf Medical

Episurf Medical AB (Nasdaq: EPIS B) has, pursuant to previously announced information, carried out a rights issue of units consisting of shares of series B and warrants of series TO14 B. The rights issue has resulted in a change in the number of shares and votes in the company. Through the rights issue, the number of shares has increased by 979,597,038 shares of series B and the number of votes has increased by 979,597,038.

Furthermore, the company has, pursuant to previously announced information, carried out a set-off issue of units consisting of shares of series B and warrants of series TO14 B directed to certain guarantors in the rights issue. The set-off issue has resulted in a change in the number of shares and votes in the company. Through the set-off issue, the number of shares has increased by 27,099,648 shares of series B and the number of votes has increased by 27,099,648.

As a consequence of the above-mentioned changes, the total number of shares amounts to 1,659,761,378, of which 473,357 are shares of series A and 1,659,288,021 are shares of series B, and the total number of votes amounts to 1,660,708,092.

## For more information, please contact:

Pål Ryfors, CEO and interim CFO, Episurf Medical  
Tel: +46 709 62 36 69  
Email: [pal.ryfors@episurf.com](mailto:pal.ryfors@episurf.com)

*This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 12.15 CEST on 30 September 2025.*

## About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: [www.episurf.com](http://www.episurf.com).